Felix Schumacher

Program Leader Targeted Therapeutics at Roche

Speaker

Felix Schumacher holds a PhD in Chemical Biology from University College London and degrees in Biochemistry from the Technical University of Munich. He co-founded Thiologics, a London-based bioconjugation biotech, before joining Roche pRED in 2013. Following years of leading molecular assessment and biochemical method development in Penzberg, he transitioned to the Roche Innovation Center Basel in 2020. There, as a matrix leader, he focuses on designing and realizing innovative drug delivery approaches. Since late 2024, Felix has served as the Mission Lead for the RNAHub, where he coordinates and shapes the strategic activities of Roche’s oligonucleotide community.